COVID-19

A Phase 2/3, Interventional Safety, Pharmacokinetics, and Efficacy, Open-Label, Mutli-Center, Single-Arm Study to Investigate Orally Administered PF-07321332 (Nirmatrelvir)/Ritonavir in Non-Hospitalized Symptomatic Pediatric Participants with COVID-19 who are at risk of progression to severe disease study